TrialThe breast journal2020

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Karen A Gelmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.